Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock

Critical Care Medicine

Volumn 32, Issue 1, 2004, Pages 21-30

  López, Angel ^a   Lorente, Jose Angel ^b   Steingrub, Jay ^c,d   Bakker, Jan ^e   McLuckie, Angela ^f   Willatts, Sheila ^g   Brockway, Michael ^h   Anzueto, Antonio ⁱ   Holzapfel, Laurent ^j   Breen, Desmond ^k   Silverman, Michael S ^l   Takala, Jukka ^m   Donaldson, Jill ⁿ   Arneson, Carl ^o   Grove, Geraldine ⁿ   Grossman, Steven ^o   Grover, Robert ⁿ  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^c BAYSTATE MEDICAL CENTER   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Locatie Lukas   (Netherlands)

^f GUY S HOSPITAL   (United Kingdom)

^g BRISTOL ROYAL INFIRMARY   (United Kingdom)

^h St Johns Hospital   (United Kingdom)

ⁱ SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^j Hopital de Fleyriat   (France)

^k ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^l Oshawa General Hospital   (Canada)

^m KUOPIO UNIVERSITY HOSPITAL   (Finland)

ⁿ GLAXOSMITHKLINE   (United Kingdom)

^o GLAXOSMITHKLINE   (United States)

more..

Author keywords

Dobutamine; Dopamine; Human; NG methyl L arginine hydrochloride; Nitrate; Nitric oxide; Nitric oxide synthase inhibitor; Norepinephrine; Placebo controlled study; Resolution of shock; Septic shock; Severe sepsis

Indexed keywords

ADRENALIN; DOBUTAMINE; DOPAMINE; DOPEXAMINE; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; PHENYLEPHRINE; VASOACTIVE AGENT;

ADULT; AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR EFFECT; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; FOLLOW UP; HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NORTH AMERICA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SIDE EFFECT; SURVIVAL;

EID: 4444273012     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000105581.01815.C6     Document Type: Article

References (30)

1. Parrillo JE, Parker MM, Natanson C, et al: Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-242
2. Rangel-Frausto M, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study. JAMA 1995; 273:117-123
3. Rees DD, Moncada S: Induction by endotoxin of a Ca-independent nitric oxide synthase in the vasculature and its pathological role in endotoxin shock. In: Clinical Relevance of Nitric Oxide in the Cardiovascular System. Moncada S, Higgs EA, Barrazueta JR (Eds). Madrid, Edicomplet, 1991, pp 69-87
4. Kilbourn RG, Griffith OW: Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst 1992; 84:827-831
5. Moncada S, Palmer RM, Higgs EA: Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43:109-142
6. MacNaul KL, Hutchinson NI: Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun 1993; 196:1330-1334
7. Cobb J, Danner R: Nitric oxide and septic shock. JAMA 1996; 275:1192-1196
8. Lorente JA, Landin L, de Pablo R, et al: L-arginine pathway in the sepsis syndrome. Crit Care Med 1993; 21:1287-1295
9. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595
10. Booke M, Meyer J, Lingnau W, et al: Use of nitric oxide synthase inhibitors in animal models of sepsis. New Horiz 1995; 3:123-138
11. Palmer RMJ: The discovery of nitric oxide in the vessel wall: A unifying concept in the pathogenesis of sepsis. Arch Surg 1993; 128:396-401
12. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012
13. Brady AL, Poole-Wilson PA: Circulatory failure in septic shock: Nitric oxide, too much of a good thing? Br Heart J 1993; 70:103-105
14. Wylam ME, Samsel RW, Umans JG: Endotoxin in vivo impairs endothelium-dependent relaxation of canine arteries in vitro. Am Rev Respir Dis 1990; 142:1263-1267
15. Julou-Schaeffer G, Gray GA, Fleming I: Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990; 259(4 Pt 2):H1038-H1043
16. Geng YJ, Hansson GK, Holme E: Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res 1992; 71:1268-1276
17. G-methyl-L- arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs. Crit Care Med 1994; 22:1835-1840
18. Cobb JP, Natanson C, Quezado ZM, et al: Differential hemodynamic effects of L-NMMA in endotoxemic and normal dogs. Am J Physiol 1995; 268:H1634-H1642
19. Rees DD, Monkhouse JE, Cambridge D, et al: Nitric oxide and the haemodynamic profile of endotoxin shock in the conscious mouse. Br J Pharmacol 1998; 124:540-546
20. Schlag G, Redl H, Gasser H, et al: Protective effects of NO synthase inhibition in a baboon model of severe sepsis. Crit Care Med 1997; 25(Suppl A3):153
21. G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock. Crit Care Med 1999; 27:913-922
22. Avontuur JA, Tutein-Nolthenius RP, van Bodegom JW, et al: Prolonged inhibition of nitric oxide synthesis in severe septic shock: A clinical study. Crit Care Med 1998; 26:660-667
23. G-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled, multicenter study (study no. 144-002). Crit Care Med 2004; 32:1-12
24. G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004; 32:13-20
25. Bone RC, Fisher CJ, Clemmer TP, et al: Sepsis syndrome: A valid clinical entity. Crit Care Med 1989; 17:389-393
26. Le Gall JR, Lemeshow S, Leleu G, et al: Customized probability models for early severe sepsis in adult intensive care patients: Intensive Care Unit Scoring Group. JAMA 1995; 273:644-650
27. Whitehead J: The Design and Analysis of Sequential Clinical Trials. Chichester, UK: Ellis Horwood, 1983
28. Whitehead J, Stratton I: Group sequential clinical trials with triangular continuation regions. Biometrics 1983; 39:227-236
29. G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 1990; 172:1132-1138
30. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1477